FDA approves drug combo for metastatic non-small cell lung cancer

Specialist researcher holding microscope slide analyzing blood sample working at coronavirus vaccine development during virus examination in microbiology hospital laboratory. Biochemistry experiment

The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumor aberrations.

Study: Which people with chronic pancreatitis will develop diabetes?

Previous article

The Prestigious THEA 2023 Awards Are Out! See Here

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations